← Back to all trials
Completed
NCT07254325
Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers
Conditions: Psoriasis
Sex: Male
Ages: 18 Years – 45 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 114
Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
Location: Shanghai Jiaotong University School of Medicine Shanghai
Summary
This is a randomized, double-blinded, controlled Phase I study of new process CMAB015 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of new process CMAB015 versus Cosentyx(Secukinumab ) in healthy male subjects after a single dose.
Eligibility Criteria
Inclusion Criteria:
1. Healthy male volunteers, age ranged 18 to 45 years (both inclusive);
2. Subjects with body weight of ≥50 kg and ≤ 75 kg and BMI ≥18 and \
Source: ClinicalTrials.gov (NCT07254325). StuddyBuddy aggregates publicly available trial information.